Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells

Investigational New Drugs

Volumn 16, Issue 3, 1998, Pages 221-225

  Izbicka, Elzbieta ^a   Lawrence, Richard ^a   Davidson, Karen ^a   Rake, James B ^b   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

^b Sanofi Research Division   (United States)

Author keywords

Human tumor cloning; SW 33377; Thioxanthones

Indexed keywords

N [[1 [[2 (DIETHYLAMINO)ETHYL]AMINO] 9 OXO 9H THIOXANTHEN 4 YL]METHYL]METHANESULFONAMIDE; SR 233377; SW 33377; SW 68210; SW 71425; THIOXANTHENE DERIVATIVE; UNCLASSIFIED DRUG; WIN 68210; WIN 71425;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CARDIOTOXICITY; CLINICAL TRIAL; COLON CANCER; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPLANT; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; SULFONAMIDES; THIOXANTHENES; TUMOR CELLS, CULTURED;

EID: 0032428289     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006152100299     Document Type: Article

References (7)

1. Thull U, Testa B: Screening of unsubstituted cyclic compounds as inhibitors of monoamine oxidases. Biochem Pharmacol 47: 2307-2310, 1994
2. Wentland U, Perni RB, Huang JI, Powless RG, Aldous SC, Klingbeil KM, Peverly AD, Robinson RG, Corbett TC, Rake JB: Thioxanthone antitumor agents: effects of variations of the 1- and 9-position of SW 33377 on antitumor activity. Proc Am Assoc Cancer Res 36: A2271, 1995
3. Coughlin S, Danz D, Klingbeil K, Robinson R, Perni R, Wentland M, Rake J: Mechanism of action of 4-aminomethylthioxanthen-9-one anti-solid tumor agents. Proc Annu Meet Am Assoc Cancer Res 34: A2271, 1993
4. Corbett T, Lowichik N, Pugh S, Polon L, Panchapor C, White K, Knight J, Demchick L, Jones J, Jones L: Solid tumor activity of SW 33377 and analogs. Proc Natl Meet Am Assoc Cancer Res 36: A2318, 1995
5. LoRusso P, Foster B, Wozniak A, Graham M, Purvis J, Rake J, Lockwood G, Valdivieso M: Phase I pharmacokinetic study of the novel antitumor agent SW 33377 given every 28 days. Proc Natl Meet Am Assoc Cancer Res 37: A1148, 1996
6. Corbett T, Lowichik N, Pugh S et al.: Antitumor activity of N-[[1[[2-(diethylamino)ethyl]amino]-9-oxo-9H-Thioxanthen-4-yl]methyl] methanesulfonamide (WIN 33377) and analogs. Expert Opinion Invest Drugs 3: 1281-1292, 1994
7. Clark G, Von Hoff D: Statistical considerations for in vitro/in vivo correlations using a cloning system. In: Dendy P and Hill B (eds) Human Tumor Drug Sensitivity Testing In Vitro. Academic Press, New York, 1983, pp 225-233